Patents by Inventor Dana Kennedy

Dana Kennedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20180369317
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: September 11, 2018
    Publication date: December 27, 2018
    Inventors: Eric Sievers, Dana Kennedy
  • Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
    Patent number: 10098963
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: October 16, 2018
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy
  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20170281794
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: June 14, 2017
    Publication date: October 5, 2017
    Inventors: Eric Sievers, Dana Kennedy, Nathan Ihle, Michael Sun
  • Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
    Patent number: 9713648
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: July 25, 2017
    Assignee: Seattle Genetics, Inc.
    Inventors: Eric Sievers, Dana Kennedy
  • WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES
    Publication number: 20160129130
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: November 11, 2015
    Publication date: May 12, 2016
    Inventors: Eric Sievers, Dana Kennedy, Nathan Ihle, Michael Sun
  • Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
    Patent number: 9211319
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: December 15, 2015
    Assignee: Seattle Genetics, Inc.
    Inventors: Eric Sievers, Dana Kennedy, Nathan Ihle, Michael Sun
  • Post-relapse treatment of CD30 expressing lymphomas
    Patent number: 8758758
    Abstract: Methods for the retreatment of CD30-expressing lymphomas with an anti-CD30 vc-PAB-MMAE antibody-drug conjugate are provided.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: June 24, 2014
    Assignee: Seattle Genetics, Inc.
    Inventors: Eric Sievers, Dana Kennedy
  • Weekly Dosing Regimens for Anti-CD30 VC-PAB-MMAE Antibody Drug-Conjugates
    Publication number: 20110268751
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A—is a Stretcher unit, and p is from about 3 to about 5.
    Type: Application
    Filed: January 8, 2010
    Publication date: November 3, 2011
    Applicant: Seattle Genetics, Inc.
    Inventors: Eric Sievers, Dana Kennedy, Nathan Ihle, Michael Sun